RxDoctor Payments Data

Becky Wade, MD

Internal Medicine · Ventura, CANPI 1992869986

Payments from drug & device makers

$338in general payments, 2019–2025

Across 18 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$81
  • Boehringer Ingelheim$49
  • Amgen$43
  • Novo Nordisk$42
  • Merck$37
  • AstraZeneca$36
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott4$81
Boehringer Ingelheim3$49
Amgen2$43
Novo Nordisk2$42
Merck2$37
AstraZeneca2$36
Ascend Therapeutics US, LLC1$25
Mayne Pharma Commercial LLC1$13
Pfizer1$11

How this compares

$338 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$224,168
Medicare patients
406
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide87$110,535
JardianceEmpagliflozin81$97,247
Cosentyx Sensoready (2 Pens)Secukinumab12$84,320
EliquisApixaban80$78,726
OzempicSemaglutide53$56,440
XareltoRivaroxaban34$43,560
ProliaDenosumab17$28,642
MounjaroTirzepatide20$26,433
FarxigaDapagliflozin Propanediol27$25,508
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$21,686
Spiriva RespimatTiotropium Bromide13$16,785
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$13,171
JanuviaSitagliptin Phosphate13$12,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$8,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$49$114,03194 claims
PfizerEliquis$11$78,72680 claims
Novo NordiskOzempic$42$56,44053 claims
AmgenProlia$43$28,64217 claims
AstraZenecaFarxiga$36$25,50827 claims
MerckJanuvia$37$12,30713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →